Active	Status	Sponsor type	Region	Phase	Filter
2 Active 2 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
SENL-B19 / SenlangBio
NCT03312205: CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies	Recruiting	1/2	50	RoW	Autologous CAR-T cells	Hebei Senlang Biotechnology Inc., Ltd., Hebei Yanda Ludaopei Hospital, Beijing Lu Daopei Hospital	Leukemia, Lymphoma, Multiple Myeloma of Bone (Diagnosis)	08/19	08/23
CTR20221359: Phase I clinical study of Senl_B19 autologous T cell injection in the treatment of r/r B-ALL	Recruiting	1	18	China	SENL-B19 - SenlangBio	Hebei Senlang Biotechnology Co., Ltd.	Relapsed/refractory CD19-positive B-cell acute lymphoblastic leukemia

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
SENL-B19 / SenlangBio
NCT03312205: CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies	Recruiting	1/2	50	RoW	Autologous CAR-T cells	Hebei Senlang Biotechnology Inc., Ltd., Hebei Yanda Ludaopei Hospital, Beijing Lu Daopei Hospital	Leukemia, Lymphoma, Multiple Myeloma of Bone (Diagnosis)	08/19	08/23
CTR20221359: Phase I clinical study of Senl_B19 autologous T cell injection in the treatment of r/r B-ALL	Recruiting	1	18	China	SENL-B19 - SenlangBio	Hebei Senlang Biotechnology Co., Ltd.	Relapsed/refractory CD19-positive B-cell acute lymphoblastic leukemia